Safety and efficacy of pralsetinib in RET fusion–positive non-small-cell lung cancer including as first-line therapy: update from the ARROW trial

1. Griesinger, F.
2. Curigliano, G.
3. Thomas, M.
4. Subbiah, V.
5. Baik, C.S.
6. Tan, D.S.W.
7. Lee, D.H.
8. Misch, D.
9. Garralda, E.
10. Kim, D.-W.
11. van der Wekken, A.J.
12. Gainor, J.F.
13. Paz-Ares, L.
14. Liu, S.V.
15. Kalemkerian, G.P.
16. Houvras, Y.
17. Bowles, D.W.
18. Mansfield, A.S.
19. Lin, J.J.
20. Smoljanovic, V.
21. Rahman, A.
22. Kong, S.
23. Zalutskaya, A.
24. Louie-Gao, M.
25. Boral, A.L.
26. Mazières, J.
27. Show all authors +

Export

Export

×

MLA

modern-language-association

APA

apa

Chicago

chicago-fullnote-bibliography

Harvard

harvard-cite-them-right

Vancouver

vancouver-author-date

---

RIS BibTex

Export

×

This document cannot be exported because it belongs to another portal.

Full text

lock_openFull text externo

DOI: 10.1016/J.ANNONC.2022.08.002 GOOGLE SCHOLAR lock_openOpen access editor

Data source: Scopus